← Leaderboards
Richard Wagner
Medosome Biotec, Llc
$2,750,049
Attributed
$3,216,562
Total exposure
6
Grants
6
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $1.5M · FY2015–23$2M$1.5M$1M$500K$0
'15
'16
'17
'18
'19
'20
'21
'22
'23
Funding mix
By agency
NIH$3,094,123 · 5
FDA$122,439 · 1
By mechanism
R44$1,611,097 · 1
R43$904,872 · 4
R42$700,593 · 1
Top collaborators
- Scott A. Rivkees1 shared
- Gary P. Wang1 shared
Others in their field
Top investigators on “Play”
- Lawrence Corey · Fred Hutchinson Cancer Center$428,785,907
- Chanza Baytop · Westat, Inc.$271,217,917
- Richard K. Wilson · Washington University$200,435,757
- Glenda E Gray · Wits Health Consortium (Pty), Ltd$196,976,947
- Jeffrey P Krischer · University Of South Florida$191,869,794
- Constance Ann Benson · University Of California, San Diego$187,132,366
Research focus
PlayTechnologyGenesPharmaceutical PreparationsCostUniversitiesFloridaNovel StrategiesLaboratoriesClinical TrialsNext GenerationResponseDeep SequencingDrug ResistanceCommercializationAftercareCommunicable DiseasesMinorAmericasIn VitroAntiviral TherapyInnovationAntiviral AgentsAmerican
Grant awards (7)
Engineering next generation probiotics for delivery of therapeutics$325,000
R43 · FY2023 · TR · contact PI
Next generation quantitative HCV drug resistance assay$776,646
R44 · FY2022 · DK · contact PI
Next generation quantitative HCV drug resistance assay$834,451
R44 · FY2021 · DK · contact PI
Prevention of White Matter Injury in Premature Infants$700,593
R42 · FY2021 · HD · contact PI
Optimization of recombinant probiotics for oral delivery of ACE2/Ang-(1-7$225,000
R43 · FY2019 · HL · contact PI
Next generation quantitative HCV drug resistance assay$232,433
R43 · FY2017 · DK · contact PI
Rapid Haplotyping procedure for determining the response of patients to DCA$122,439
R43 · FY2015 · FD · contact PI